Goodwill and Intangible Assets, Net (Details Narrative) |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2024
USD ($)
|
Sep. 30, 2023
USD ($)
|
Jun. 30, 2023
USD ($)
|
Mar. 31, 2023
USD ($)
|
Dec. 31, 2022
USD ($)
|
Sep. 30, 2024
USD ($)
|
Sep. 30, 2023
USD ($)
|
Dec. 31, 2023
USD ($)
Integer
|
Dec. 31, 2022
USD ($)
|
Dec. 31, 2021
USD ($)
|
|
| Indefinite-Lived Intangible Assets [Line Items] | ||||||||||
| Number of reporting units | Integer | 3 | |||||||||
| Goodwill, impairment loss | $ 82,714,000 | $ 0 | $ 29,633,000 | $ 3,610,000 | $ 112,347,000 | $ 112,347,000 | $ 3,610,000 | |||
| Amortization of acquired intangible assets | 375,000 | 553,000 | 1,377,000 | 1,640,000 | 2,193,000 | 2,193,000 | ||||
| Goodwill | 7,347,000 | $ 119,694,000 | 7,347,000 | 7,347,000 | 119,694,000 | $ 123,304,000 | ||||
| Impairment of intangible assets | $ 0 | $ 0 | ||||||||
| Other [Member] | ||||||||||
| Indefinite-Lived Intangible Assets [Line Items] | ||||||||||
| Goodwill, impairment loss | 82,714,000 | 112,347,000 | $ 112,347,000 | $ 3,610,000 | ||||||
| Cell Therapy Clinical Trial Update [Member] | In Process Research and Development [Member] | ||||||||||
| Indefinite-Lived Intangible Assets [Line Items] | ||||||||||
| Impairment of intangible assets | $ 107,800,000 | $ 107,800,000 | ||||||||
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|